↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Mobia Medical$MOBI · filed: 🫧 Edgar looked up MOBIA MEDICALCheck ▾Close ▴
What Mobia Medical filed
🫧 Edgar looked up MOBIA MEDICAL, INC. ($MOBI). Last filing: 10-Q, 2026-11-05. 5 event filings (8-K) in the past twelve months. Every figure links to the filing it came from on Mobia Medical’s card.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
**$150M** neuromodulation IPO prices this week; book composition and installed base metrics will dictate aftermarket stability.
$150 million
initial public offering
$400M-$600M
range if the company dilutes 20-25 percent
50-100
active sites and
500-1,000
procedures annually at IPO tend to command revenue multiples…
Mobia Medical set terms this week for a $150 million initial public offering, pricing a nerve stimulation device platform into a market that has shown uneven tolerance for pre-revenue medical technology. The company filed terms without disclosing final share count or range, a common late-stage maneuver that suggests underwriters are still calibrating demand.
The offering lands in the neuromodulation subsector, where devices deliver electrical impulses to nerves for pain management, motor function restoration, or autonomic regulation. Mobia's specific indication set remains undisclosed in public filings, but the $150 million raise positions the company among mid-cap medtech entries rather than platform-scale bioelectronics plays. Pricing this week means the roadshow compressed into three to four days, typical for offerings with pre-committed anchor demand or favorable prior crossover rounds.
The IPO follows a calendar quarter in which medtech listings underperformed software and industrials on a total-return basis, but outperformed traditional biopharma. Nerve stimulation devices occupy a regulatory middle ground: Class II or Class III designations depending on invasiveness, reimbursement pathways that lean on existing CPT codes if the device maps to established procedures, and commercialization timelines measured in quarters rather than years. That profile appeals to growth allocators who avoid binary Phase III risk but want exposure to high-margin hardware with consumable attach rates. The $150 million figure implies either a modest valuation with substantial insider rollover, or a pre-money in the $400M-$600M range if the company dilutes 20-25 percent, standard for venture-backed medtech at this stage.
Two factors warrant tracking. First, whether Mobia discloses installed base or procedure volumes in the final prospectus. Device companies with 50-100 active sites and 500-1,000 procedures annually at IPO tend to command revenue multiples in the 6x-10x range if growth exceeds 40 percent year-over-year. Second, the composition of the book. If crossover funds that backed Neuronetics, Nevro, or Nalu Medical appear as cornerstone investors, the aftermarket will likely stabilize above issue price. If the book tilts retail or generalist growth funds, volatility in the first 30 days becomes the base case.
Pricing likely occurs Wednesday or Thursday. The underwriter syndicate, lock-up terms, and any greenshoe over-allotment structure will clarify whether this is a company going public to fund a pivotal trial, scale commercialization of an approved device, or provide liquidity to early backers. The neuromodulation device market grew 12 percent in trailing-twelve-month revenue across public comps, but valuations compressed 18 percent in the same window, a spread that makes timing critical.
Mobia's S-1 amendment with final pricing will surface by market close Tuesday, two trading sessions before the expected first-day pop or fade.
Branded by POPS4 · proof in 60 seconds
For the principal
Watch S-1 final amendment for revenue per site and reimbursement pathway clarity before any allocation decision.
For the operator
Comp the book to Nevro and Neuronetics crossover rounds; aftermarket pattern repeats if same names anchor.
For the house
No named-account position pre-pricing; evaluate post-issue if procedure volumes exceed 1,000 quarterly and multiples compress below 7x.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.